This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.0 | Synonyms: Infantile congenital pure red cell aplasia, Diamond-Blackfan anemia (infantile type), DBA, Congenital hypoplastic anemia (infantile type)
Congenital pure red cell aplasia occurring in infancy was first described as an independent disease entity in 1938 by the American pediatricians Louis K. Diamond and Kenneth D. Blackfan. They reported a syndrome of severe anemia and reticulocytopenia with normal white blood cell and platelet counts in 7 infants, and presented a marked reduction of erythroid precursors with normal findings in the other lineages on bone marrow examination as its characteristic. The disease later became known as Diamond-Blackfan anemia (DBA).
In the 1940s–1960s, there was theoretical debate over the pathogenesis of this disease. Some researchers argued for an intrinsic hematopoietic defect, while others proposed an immune-mediated mechanism. In 1951, Gasser, noting that the disease occurs predominantly in infancy, proposed classifying it as an infantile type. Subsequently, as response to corticosteroid treatment was confirmed, a treatment paradigm began to be established.
In 1999, Draptchinskaia et al. identified RPS19 (ribosomal protein S19) as the first DBA-causing gene, suggesting that impaired ribosome biogenesis (ribosomopathy) is the core pathogenesis of DBA. Throughout the 2000s, variants in many ribosomal protein genes such as RPS24, RPS17, RPL35A, RPL5 and RPL11 were confirmed to be associated with DBA, establishing DBA as the representative disease of the ribosomopathies.
In Korea, since the 2000s, registration and follow-up of patients with DBA have been carried out mainly by the Korean Society of Pediatric Hematology-Oncology. Domestic multicenter studies have confirmed various ribosomal protein gene variants, including RPS19 variants, in Korean patients as well, and data on hematopoietic stem cell transplantation outcomes are also accumulating.
The main cause of infantile congenital pure red cell aplasia is heterozygous loss-of-function variants in genes encoding ribosomal proteins. To date, variants in about 20 or more ribosomal protein genes (RPS19, RPL5, RPL11, RPL35A, RPS24, RPS17, RPS26, RPS10, RPL26, RPL15, etc.) have been confirmed to be associated with DBA. RPS19 variants are the most common, accounting for about 25% of all patients with DBA.
| Gene | Ribosomal subunit | Frequency (%) | Notes |
|---|---|---|---|
| RPS19 | 40S | About 25% | Most common cause, diverse clinical phenotypes |
| RPL5 | 60S | About 9% | High frequency of accompanying thumb anomalies and cleft palate |
| RPL11 | 60S | About 7% | High frequency of accompanying thumb anomalies |
| RPL35A | 60S | About 3% | Mild to moderate phenotype |
| RPS26 | 40S | About 3% | Tendency toward anemia alone without malformations |
| Unknown | - | About 35–40% | Presumed unidentified gene variants |
Some DBA-like syndromes can be caused by variants of the GATA1 gene (X-linked). In addition, variants of the TSR2 gene, a pre-ribosomal protein binding factor, also cause a DBA-like phenotype. In about 35–40% of all patients with DBA, the causative gene variant is not identified by current molecular genetic testing, and new causative genes continue to be discovered with advances in next-generation sequencing (NGS) technology.
About 40–45% of infantile congenital pure red cell aplasia (DBA) is hereditary with a family history, and most of these follow an autosomal dominant inheritance pattern. About 55–60% of all patients have the sporadic (de novo variant) form without a family history. Rarely, autosomal recessive or X-linked (GATA1, TSR2 variants) inheritance patterns have been reported.
Heterozygous deletions or loss-of-function variants of ribosomal protein genes cause impaired assembly of ribosomal subunits. Under ribosomal stress, the p53 pathway is overactivated, promoting selective apoptosis of erythroid progenitors (BFU-E, CFU-E). Erythroid progenitors are known to be particularly vulnerable to ribosomal protein imbalance compared with other blood cell lineages, which is related to the translation-dependent regulation of expression of the GATA1 transcription factor.
Incomplete penetrance is observed, with clinical phenotypes varying even within families carrying the same gene variant. RPL5 and RPL11 variants in particular are frequently accompanied by thumb anomalies (triphalangeal thumb) and cleft palate.
Infantile congenital pure red cell aplasia is a rare disease, with a worldwide incidence of 5–7 per million births reported. Some studies estimate it at 1/100,000–1/200,000 live births. There is no or only a slight sex difference, and there are no consistent reports of higher frequency in specific ethnic groups.
More than 90% of diagnoses are made within the first year of life, and the median age of onset is 2–3 months. Some patients are diagnosed in the neonatal period (within a few days to weeks of birth), and rarely there are cases diagnosed after school age or in adulthood.
In Korea, Diamond-Blackfan anemia is registered in the rare disease registry program. Health Insurance Review & Assessment Service (HIRA) rare disease statistics report about 20–40 newly registered patients per year. Registration and follow-up are carried out continuously within pediatric hematology-oncology departments.
The Diamond-Blackfan Anemia Registry (DBAR, USA), the DBA Registry of the European Working Group on Diamond-Blackfan Anemia (EWOG-DBA), the Japanese DBA research group and others are collecting data. Through these registries, long-term clinical course, treatment response and complication frequency are being systematically analyzed.
Heterozygous variants of ribosomal protein genes cause reduced production of the corresponding ribosomal protein, which leads to an imbalance of free ribosomal proteins. Excess free ribosomal proteins (especially RPL5 and RPL11) bind to MDM2, inhibiting ubiquitination of p53, and as a result the p53 protein is stabilized. Overactivation of p53 induces cell cycle arrest and apoptosis, so that erythroid progenitors are selectively lost.
Erythroid progenitors (especially at the BFU-E and CFU-E stages) require high levels of protein synthesis and ribosomes for rapid proliferation and differentiation. In addition, the expression of GATA1, a transcription factor key to erythroid differentiation, is regulated in a translation-dependent manner, making it particularly vulnerable when ribosomal function is reduced. This selective vulnerability explains why aplasia appears only in erythroid cells.
In some patients with DBA, reduced EPO receptor signaling or reduced responsiveness to EPO in erythroid progenitors is observed. Serum EPO is generally elevated above normal, so EPO deficiency is not the cause. The fact that normal red cell production is restored after HSCT supports the view that the main defect of DBA lies in the intrinsic hematopoietic progenitors.
The main symptoms of infantile congenital pure red cell aplasia are those of severe anemia. In infants, pallor, feeding difficulty, tachypnea, tachycardia, irritability or lethargy appear. In most patients, symptoms begin within the first few months of life, and parents often present with skin pallor or feeding problems as the chief complaint. In severe anemia, congestive heart failure and hepatomegaly may develop.
Patients with infantile congenital pure red cell aplasia have various congenital anomalies in about 30–47% of cases. The most prominent anomaly is thumb abnormality (triphalangeal thumb, or flattened thumb). Cleft lip and palate, plagiocephaly, strabismus, congenital heart defects, genitourinary anomalies and others are also reported. Thumb abnormalities are particularly strongly associated with RPL5 and RPL11 variants.
In patients receiving long-term corticosteroid treatment, growth impairment, Cushing syndrome-like symptoms and osteoporosis become problems. In patients receiving chronic transfusion, endocrine disorders due to iron overload may occur. Patients with DBA have an increased risk of malignancy compared with the general population, with particularly high risks of AML, MDS, osteosarcoma, colon cancer and others.
On physical examination, severe pallor, tachycardia and tachypnea are observed. Splenomegaly is typically absent or mild, which is an important point of differentiation from hemolytic anemia. Scleral icterus is generally absent. When congenital anomalies are present, thumb anomalies, skull abnormalities and cardiac anomalies are found.
Complete blood count (CBC) shows normocytic normochromic or macrocytic anemia (Hb generally 3–8 g/dL). The reticulocyte count is markedly reduced or absent (reticulocytes 0–1%). White blood cell count and differential are normal, and the platelet count is also normal or mildly increased. Increased erythrocyte adenosine deaminase (eADA) activity is characteristically observed in DBA (about 80–90% of all cases).
Bone marrow aspiration and biopsy are characterized by severe reduction or absence of erythroid precursors. Myeloid (granulocytic) and megakaryocytic cells are present normally. In patients with DBA, the proportion of fetal hemoglobin (HbF) remains abnormally high for age, which is used as a supportive diagnostic indicator.
Infantile congenital pure red cell aplasia is not included in the standard newborn screening (NBS) panel. When unexplained anemia and reticulocytopenia are found in an infant, DBA is suspected and further testing is performed. When congenital anomalies are found on prenatal ultrasound, intensified hematologic evaluation after birth is recommended.
Increased eADA activity is a relatively specific biochemical marker of DBA. Because eADA is normal in anemias of other causes such as iron deficiency anemia and transient erythroblastopenia of childhood (TEC), it can be used as a useful first-line screening test for differentiating the cause of anemia. When the test is positive, a stepwise approach proceeding to bone marrow examination and molecular genetic testing is standard.
Hematologic screening of the parents and siblings of patients with DBA is recommended. Family screening is also important for genetic counseling and for later selection of hematopoietic stem cell donors.
The currently used diagnostic criteria for DBA are as follows: (1) normocytic or macrocytic anemia diagnosed before age 1, (2) reticulocytopenia, (3) reduced erythroid precursors in the bone marrow and (4) normal white blood cells and platelets. When these criteria are met, classic DBA is diagnosed; when confirmed by a gene variant or family history, the diagnosis can be made even if some criteria are not met.
The causative variant is identified through a ribosomal protein gene panel (RPS19, RPL5, RPL11, RPL35A, RPS24, RPS17, RPS26, etc.) or whole-exome sequencing (WES). Analysis of large deletions/duplications by MLPA is also performed. Molecular genetic testing is essential not only for confirming the diagnosis but also for family screening, genetic counseling and selection of transplant donors.
Transient erythroblastopenia of childhood (TEC) is distinguished from DBA in that it recovers spontaneously after age 2 and eADA is normal. Fanconi anemia is differentiated by pancytopenia and DEB/MMC testing. Pearson syndrome is differentiated by mitochondrial DNA deletion.
Corticosteroids (mainly prednisolone) are the first-line treatment for infantile congenital pure red cell aplasia. The treatment response rate is about 70–80%. Prednisolone is started at 2 mg/kg/day (maximum 60 mg/day) and tapered to the minimum effective dose after response. Because long-term steroid treatment causes adverse effects such as growth impairment, Cushing syndrome, susceptibility to infection and osteoporosis, the lowest possible dose and alternate-day dosing are recommended.
In patients who do not respond to steroids or have severe steroid adverse effects, regular transfusion therapy is the alternative. Packed red blood cell (PRBC) transfusion is generally given every 4–6 weeks to maintain Hb > 8 g/dL. To prevent iron overload from chronic transfusion, iron chelation therapy (deferasirox, deferoxamine) is given concurrently.
Hematopoietic stem cell transplantation (HSCT) is the only curative treatment. When HSCT is performed from an HLA-matched allogeneic donor (sibling > unrelated donor), the 5-year survival is about 70–90%. The optimal timing of transplantation is generally recommended to be before age 9, and it is actively considered in cases of steroid refractoriness, transfusion dependence or when an HLA-matched donor within the family is identified.
Gene therapy clinical trials for RPS19 DBA are underway at some centers. The approach introduces a normal RPS19 gene into autologous hematopoietic stem cells using a lentiviral vector. Luspatercept is being studied in some adult patients with DBA, and early clinical results are encouraging.
Patients with a sustained response to steroids (about 40% of the total) have a relatively good prognosis. Entry into long-term remission after steroid response has been reported in about 20% of patients. When HSCT from an HLA-matched donor is performed early, long-term survival is high. When patients are steroid-refractory and HSCT is not possible, they become dependent on chronic transfusion, and complications of iron overload determine long-term prognosis.
The risk of malignancy in patients with DBA is about 3–5 times higher. Some reports estimate the cumulative cancer incidence by age 40 at about 20%. The risks of AML, MDS, osteosarcoma, head and neck cancer, colon cancer and others are also increased. Therefore, regular tumor surveillance is needed.
Survival into adulthood is possible with appropriate management, but in patients dependent on chronic transfusion there is a risk of early death from cardiac siderosis, hepatic complications and infection. Steroid adverse effects (obesity, growth impairment, osteoporosis) affect quality of life, and ongoing specialist follow-up is needed in adulthood as well.
Because infantile congenital pure red cell aplasia mainly follows an autosomal dominant inheritance pattern, genetic counseling for the patient's parents and siblings is essential. When the causative gene variant is identified, molecular genetic testing is recommended for family members. When selecting a transplant donor, it is important to check in advance for DBA carriers within the family.
In families with an identified causative variant, prenatal genetic testing by chorionic villus sampling (CVS) or amniocentesis is possible in subsequent pregnancies. In in vitro fertilization cycles, preimplantation genetic testing (PGT-M) can be used to prevent implantation of affected embryos, or to select an HLA-matched sibling for use in savior sibling transplantation.
During steroid treatment, infection prevention, calcium/vitamin D supplementation and growth monitoring are carried out. In chronically transfused patients, iron chelation therapy is given regularly and cardiac and hepatic iron overload are monitored regularly. Hematologic follow-up testing at least once a year and regular checkups for early detection of malignancy are recommended.